Methemoglobinemia and acute hemolysis induced by high intravenous doses of vitamin C in a COVID-19 patient with unrecognized glucose-6- phosphate-dehydrogenase deficiency
https://doi.org/10.4081/gc.2022.10286
Accepted: 8 July 2022
HTML: 24
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
In glucose-6-phosphate-dehydrogenase deficiency (favism), exposure to oxidant agents can trigger hemolytic crises. The intravenous administration of very high doses of vitamin C was proposed as a treatment for severe coronavirus disease 2019 (COVID-19) pneumonia. Unlike low vitamin C doses, very high doses (>6 gr daily) can promote H2O2 formation, oxidation of hemoglobin to methemoglobin and, eventually, hemolytic anemia in patients with favism. We here describe the case of a 77-year old man hospitalized for severe COVID-19 pneumonia and treated with a mean daily dose of 9.5 gr of intravenous vitamin C during the first 6 days. He developed methemoglobinemia and hemolytic anemia, which improved after interruption of vitamin C treatment. Previously unrecognized glucose- 6-phophate-dehydrogenase deficiency was diagnosed. This first case of vitamin Cinduced hemolytic anemia in a COVID-19 patient indicates the need of a screening for glucose-6-phosphate-dehydrogenase deficiency before treatment with very high vitamin C doses or for long period.
References
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81. doi:10.1016/S2213-2600(20)30079-5. Erratum in: Lancet Respir Med 2020;8:e26. DOI: https://doi.org/10.1016/S2213-2600(20)30079-5
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021 Apr 21-2021 Nov 9.
Fowler AA 3rd, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA 2019;322:1261-70. doi:10.1001/jama.2019.11825. Erratum in: JAMA 2020;323:379. DOI: https://doi.org/10.1001/jama.2019.11825
Fatima A, Khan MUA, Najeeb M, et al. Role of high dose IV vitamin C and zinc in coronavirus. Geriatric Care 2021;7:9338. DOI: https://doi.org/10.4081/gc.2021.9338
Milani GP, Macchi M, Guz-Mark A. Vitamin C in the Treatment of COVID-19. Nutrients 2021;13:1172. DOI: https://doi.org/10.3390/nu13041172
Zhang J, Rao X, Li Y, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care 2021;1:5. DOI: https://doi.org/10.1186/s13613-020-00792-3
Said EA, Al-Reesi I, Al-Shizawi N, et al. Defining IL-6 levels in healthy individuals: a meta-analysis. J Med Virol 2021;93:3915-24. DOI: https://doi.org/10.1002/jmv.26654
Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood 2020;136:1225-40. DOI: https://doi.org/10.1182/blood.2019000944
Rehman A, Shehadeh M, Khirfan D, Jones A. Severe acute hemolytic anaemia associated with severe methemoglobinemia in a G6PD-deficient man. BMJ Case Rep 2018;2018:bcr2017223369. DOI: https://doi.org/10.1136/bcr-2017-223369
Lo YH, Mok KL. High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Am J Emerg Med 2020;38:2488.e3-2488.e5. DOI: https://doi.org/10.1016/j.ajem.2020.05.099
Ibrahim IH, Sallam SM, Omar H, Rizk M. Oxidative hemolysis of erythrocytes induced by various vitamins. Int J Biomed Sci 2006;2:295-8.
Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2011;2:78-88. DOI: https://doi.org/10.3945/an.110.000109
Lopes DV, Lazar Neto F, Marques LC, et al. Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: a case-report. IDCases 2021;23:e01013. DOI: https://doi.org/10.1016/j.idcr.2020.e01013
Onori ME, Ricciardi Tenore C, Urbani A, Minucci A. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review. Mol Biol Rep 2021;48:2973-8. DOI: https://doi.org/10.1007/s11033-021-06234-y
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. DOI: https://doi.org/10.1038/clpt.1981.154
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
